Manijeh Contractor, MD
Ophthalmology · Troy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Albany Troy Cataract and Laser Associates · 11 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Contractor’s office at (518) 274-3123 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$322,194
Medicare paid this office $322,194 for 547 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 25 | $174,119 | None |
| Established patient complete exam of visual system | 475 | $52,539 | $77 |
| Injection of drug into eye | 32 | $14,237 | $81 |
| Imaging of retina | 190 | $9,575 | $26 |
| Established patient problem focused exam of visual system | 72 | $6,139 | $55 |
See all 11 services
| Injection, aflibercept, 1 mg | 25 | $174,119 | None |
| Established patient complete exam of visual system | 475 | $52,539 | $77 |
| Injection of drug into eye | 32 | $14,237 | $81 |
| Imaging of retina | 190 | $9,575 | $26 |
| Established patient problem focused exam of visual system | 72 | $6,139 | $55 |
| Photography of the retina | 153 | $4,565 | $23 |
| Exam of visual field with extended testing | 70 | $3,306 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 14 | $1,054 | $75 |
| Imaging of optic nerve | 41 | $1,053 | $22 |
| Return visit (30+ min) | 16 | $731 | $37 |
| 2d ultrasound scan of eye tissue and structures | 13 | $443 | $30 |
Who their Medicare patients are
547 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 19% · Women 60% · Also on Medicaid 11% · Health risk score 1.19. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 34% · Coronary heart disease 33% · Chronic kidney disease 23% · Depression 19% · Heart failure 17% · Cancer 16% · Atrial fibrillation 16% · COPD 12% · Stroke 10% · Dementia 5%.
The office billed $833,331, Medicare allowed $429,571 and paid $322,194; for 4,329 services of 26 kinds; $225,320 of it was for drugs given in the office and $96,874 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 547 | 4,329 | 76 | 1.19 | $833,331 | $322,194 |
| 2023 | 638 | 3,664 | 75 | 1.19 | $1,002,906 | $413,299 |
| 2022 | 713 | 3,835 | 75 | 1.19 | $921,571 | $393,343 |
| 2021 | 696 | 3,906 | 75 | 1.15 | $859,335 | $380,204 |
| 2020 | 503 | 2,319 | 74 | 1.23 | $468,178 | $207,687 |
| 2019 | 626 | 4,102 | 74 | 1.25 | $786,530 | $364,460 |
| 2018 | 684 | 4,374 | 74 | 1.20 | $895,167 | $408,220 |
| 2017 | 835 | 5,537 | 74 | 1.25 | $1,050,582 | $433,888 |
| 2016 | 912 | 4,616 | 74 | 1.17 | $1,169,430 | $519,560 |
| 2015 | 1,137 | 4,452 | 75 | 1.14 | $842,345 | $351,877 |
| 2014 | 949 | 3,461 | 74 | 1.18 | $596,630 | $224,323 |
| 2013 | 888 | 2,674 | 73 | 1.20 | $421,458 | $166,835 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Injection, aflibercept, 1 mg | 31 | $224,053 | None |
| Established patient complete exam of visual system | 551 | $71,762 | $87 |
| Injection of drug into eye | 38 | $19,701 | $88 |
| Imaging of retina | 244 | $13,912 | $29 |
| Established patient problem focused exam of visual system | 82 | $7,780 | $63 |
| Exam of visual field with extended testing | 101 | $5,446 | $46 |
| Photography of the retina | 175 | $5,172 | $25 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 22 | $2,117 | $92 |
| Return visit (30+ min) | 25 | $1,934 | $69 |
| Imaging of optic nerve | 53 | $1,601 | $26 |
| New patient complete exam of visual system | 14 | $1,281 | $92 |
| Photography of content of eyes | 13 | $261 | $17 |
2022: 15 services
| Injection, aflibercept, 1 mg | 28 | $156,267 | None |
| Injection, ranibizumab, 0.1 mg | 21 | $103,687 | None |
| Established patient problem focused exam of visual system | 441 | $38,174 | $65 |
| Established patient complete exam of visual system | 387 | $37,171 | $79 |
| Injection of drug into eye | 47 | $16,528 | $82 |
| Imaging of retina | 251 | $13,381 | $28 |
| Exam of visual field with extended testing | 151 | $7,964 | $45 |
| Photography of the retina | 153 | $4,798 | $26 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 27 | $2,930 | $95 |
| New patient complete exam of visual system | 20 | $2,086 | $104 |
| Imaging of optic nerve | 55 | $1,429 | $23 |
| Return visit (30+ min) | 11 | $716 | $65 |
| Microfluid analysis of tears | 16 | $711 | $22 |
| Short return visit (20+ min) | 11 | $589 | $45 |
| Photography of content of eyes | 15 | $242 | $16 |
2021: 14 services
| Injection, ranibizumab, 0.1 mg | 41 | $154,034 | None |
| Injection, aflibercept, 1 mg | 19 | $76,402 | None |
| Established patient complete exam of visual system | 574 | $74,613 | $87 |
| Injection of drug into eye | 58 | $15,520 | $87 |
| Imaging of retina | 251 | $12,966 | $30 |
| Established patient problem focused exam of visual system | 118 | $12,746 | $68 |
| Exam of visual field with extended testing | 160 | $8,630 | $44 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 58 | $5,661 | $90 |
| Photography of the retina | 130 | $4,409 | $29 |
| New patient visit (45+ min) | 19 | $1,943 | $102 |
| Imaging of optic nerve | 66 | $1,928 | $26 |
| Microfluid analysis of tears | 26 | $1,326 | $22 |
| New patient complete exam of visual system | 11 | $1,270 | $115 |
| Return visit (30+ min) | 13 | $1,115 | $86 |
2020: 11 services
| Injection, ranibizumab, 0.1 mg | 19 | $108,866 | None |
| Established patient complete exam of visual system | 424 | $46,909 | $86 |
| Imaging of retina | 170 | $7,155 | $29 |
| Injection of drug into eye | 20 | $6,673 | $75 |
| Established patient problem focused exam of visual system | 59 | $5,444 | $66 |
| Exam of visual field with extended testing | 107 | $5,319 | $45 |
| Photography of the retina | 104 | $3,580 | $30 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 40 | $3,100 | $72 |
| New patient visit (45+ min) | 23 | $2,953 | $128 |
| Imaging of optic nerve | 38 | $1,048 | $27 |
| Microfluid analysis of tears | 12 | $553 | $22 |
2019: 11 services
| Injection, ranibizumab, 0.1 mg | 27 | $223,867 | None |
| Established patient complete exam of visual system | 555 | $69,461 | $83 |
| Imaging of retina | 269 | $14,359 | $30 |
| Injection of drug into eye | 29 | $12,025 | $74 |
| Established patient problem focused exam of visual system | 132 | $10,658 | $63 |
| Exam of visual field with extended testing | 145 | $7,680 | $44 |
| Photography of the retina | 174 | $7,484 | $35 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 59 | $4,365 | $66 |
| Imaging of optic nerve | 63 | $1,842 | $25 |
| New patient visit (45+ min) | 13 | $1,536 | $118 |
| Photography of content of eyes | 13 | $204 | $15 |
2018: 16 services
| Injection, ranibizumab, 0.1 mg | 26 | $211,346 | None |
| Established patient complete exam of visual system | 586 | $87,621 | $84 |
| Injection, aflibercept, 1 mg | 11 | $27,246 | None |
| Imaging of retina | 298 | $15,566 | $29 |
| Injection of drug into eye | 28 | $12,407 | $77 |
| Photography of the retina | 213 | $9,611 | $38 |
| Exam of visual field with extended testing | 162 | $9,136 | $44 |
| Established patient problem focused exam of visual system | 100 | $7,260 | $59 |
| Long return visit (40+ min) | 62 | $6,678 | $106 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 83 | $6,014 | $62 |
| Imaging of optic nerve | 95 | $2,763 | $25 |
| Return visit (30+ min) | 27 | $2,207 | $69 |
| New patient visit (45+ min) | 21 | $2,066 | $98 |
| Microfluid analysis of tears | 16 | $705 | $22 |
| Exam of the internal drainage system of eye | 12 | $208 | $17 |
| Photography of content of eyes | 13 | $178 | $12 |
2017: 14 services
| Injection, aflibercept, 1 mg | 20 | $157,973 | None |
| Established patient complete exam of visual system | 767 | $104,888 | $82 |
| Imaging of retina | 342 | $16,645 | $28 |
| Injection of drug into eye | 30 | $12,158 | $72 |
| Exam of visual field with extended testing | 198 | $11,510 | $44 |
| Established patient problem focused exam of visual system | 106 | $9,423 | $63 |
| Photography of the retina | 163 | $8,155 | $45 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 68 | $4,414 | $58 |
| Imaging of optic nerve | 96 | $2,635 | $24 |
| New patient complete exam of visual system | 21 | $1,773 | $84 |
| Microfluid analysis of tears | 24 | $1,132 | $22 |
| Examination of eye by ophthalmoscope with retinal drawing | 13 | $474 | $36 |
| Exam of the internal drainage system of eye | 15 | $290 | $19 |
| Photography of content of eyes | 12 | $177 | $13 |
2016: 16 services
| Injection, ranibizumab, 0.1 mg | 22 | $149,247 | None |
| Injection, aflibercept, 1 mg | 17 | $149,033 | None |
| Established patient complete exam of visual system | 799 | $109,688 | $84 |
| Imaging of retina | 425 | $23,675 | $31 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 99 | $16,697 | $74 |
| Injection of drug into eye | 34 | $15,237 | $76 |
| Photography of the retina | 216 | $13,498 | $52 |
| Exam of visual field with extended testing | 201 | $11,344 | $44 |
| Established patient problem focused exam of visual system | 138 | $8,693 | $52 |
| Long return visit (40+ min) | 42 | $4,892 | $104 |
| Imaging of optic nerve | 111 | $3,774 | $29 |
| Microfluid analysis of tears | 33 | $1,808 | $22 |
| Return visit (30+ min) | 27 | $1,767 | $61 |
| New patient visit (45+ min) | 20 | $1,760 | $88 |
| Photography of content of eyes | 14 | $187 | $12 |
| Exam of the internal drainage system of eye | 11 | $141 | $13 |
2015: 19 services
| Established patient complete exam of visual system | 965 | $117,553 | $85 |
| Injection, ranibizumab, 0.1 mg | 18 | $90,434 | None |
| Imaging of retina | 451 | $22,567 | $31 |
| Established patient problem focused exam of visual system | 180 | $14,303 | $58 |
| Exam of visual field with extended testing | 229 | $13,170 | $46 |
| Photography of the retina | 204 | $12,542 | $55 |
| New patient visit (45+ min) | 104 | $10,849 | $104 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 55 | $9,233 | $76 |
| Injection of drug into eye | 24 | $6,882 | $76 |
| Imaging of optic nerve | 132 | $4,243 | $30 |
| Microfluid analysis of tears | 66 | $3,194 | $22 |
| Closure of tear duct opening using plug | 12 | $2,026 | $101 |
| Return visit (30+ min) | 19 | $1,295 | $59 |
| New patient complete exam of visual system | 12 | $1,104 | $92 |
| 2d ultrasound scan of eye tissue and structures | 14 | $923 | $58 |
| Examination of eye by ophthalmoscope with retinal drawing | 17 | $600 | $35 |
| Removal of eyelashes using forceps | 11 | $572 | $38 |
| Ultrasound scan of cornea to determine thickness | 50 | $510 | $10 |
| Exam of the internal drainage system of eye | 18 | $300 | $17 |
2014: 18 services
| Established patient complete exam of visual system | 788 | $103,835 | $86 |
| Imaging of retina | 360 | $19,848 | $33 |
| Established patient problem focused exam of visual system | 163 | $13,143 | $58 |
| Photography of the retina | 157 | $10,234 | $55 |
| Exam of visual field with extended testing | 149 | $8,267 | $46 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 49 | $8,199 | $79 |
| New patient visit (45+ min) | 72 | $7,895 | $110 |
| Injection of drug into eye | 24 | $5,508 | $76 |
| New patient complete exam of visual system | 36 | $3,314 | $92 |
| Injection, bevacizumab, 10 mg | 19 | $2,747 | None |
| Return visit (30+ min) | 40 | $2,674 | $61 |
| Imaging of optic nerve | 73 | $2,346 | $31 |
| Closure of tear duct opening using plug | 12 | $2,215 | $92 |
| Microfluid analysis of tears | 42 | $1,745 | $22 |
| 2d ultrasound scan of eye tissue and structures | 13 | $1,212 | $64 |
| Examination of eye by ophthalmoscope with retinal drawing | 23 | $929 | $34 |
| Removal of eyelashes using forceps | 13 | $552 | $37 |
| Ultrasound scan of cornea to determine thickness | 30 | $301 | $10 |
2013: 17 services
| Established patient complete exam of visual system | 654 | $85,308 | $86 |
| New patient visit (45+ min) | 117 | $12,865 | $110 |
| Established patient problem focused exam of visual system | 144 | $12,090 | $61 |
| Imaging of retina | 179 | $8,395 | $32 |
| Photography of the retina | 149 | $7,699 | $48 |
| Exam of visual field with extended testing | 112 | $6,113 | $45 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 34 | $5,208 | $77 |
| New patient complete exam of visual system | 46 | $4,440 | $97 |
| Injection of drug into eye | 16 | $3,887 | $78 |
| Return visit (30+ min) | 46 | $3,369 | $66 |
| Imaging of optic nerve | 85 | $2,695 | $31 |
| Unclassified biologics | 16 | $978 | None |
| Microfluid analysis of tears | 21 | $890 | $22 |
| Short return visit (20+ min) | 15 | $728 | $45 |
| Exam of the internal drainage system of eye | 19 | $392 | $21 |
| Ultrasound scan of cornea to determine thickness | 35 | $330 | $9 |
| Examination of eye by ophthalmoscope with retinal drawing | 16 | $329 | $21 |
Medicaid work
$2,397 in 2023
Medicaid paid $2,397 for 69 billed services this clinician did in 2023, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 69 | $2,397 |
| 2023 | 69 | 1 | 24 | $2,397 |
| 2022 | 143 | 4 | 18 | $5,994 |
| 2021 | 114 | 3 | 17 | $5,037 |
| 2020 | 14 | 1 | 14 | $49 |
| 2019 | 114 | 1 | 16 | $2,670 |
| 2018 | 78 | 2 | 14 | $852 |
See the largest Medicaid services in earlier years
2022
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 88 | $3,705 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 27 | $1,559 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 14 | $625 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 14 | $105 |
2021
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 85 | $3,145 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 17 | $959 |
| Return visit (30+ min) | 12 | $932 |
2020
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 14 | $49 |
2019
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 114 | $2,670 |
2018
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 52 | $852 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 26 | $0 |
Drugs they prescribed that Part D paid
$48,148
Pharmacies billed $48,148 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 381) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
291 generic and 90 brand-name prescriptions · $48,148 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cyclosporine | 23 | $7,000 | $304 |
| Brimonidine | 22 | $2,585 | $117 |
| Brinzolamide | 13 | $1,930 | $148 |
| Valacyclovir | 22 | $1,737 | $79 |
| Erythromycin | 70 | $932 | $13 |
See all 12 drugs
| Cyclosporine | 23 | $7,000 | $304 |
| Brimonidine | 22 | $2,585 | $117 |
| Brinzolamide | 13 | $1,930 | $148 |
| Valacyclovir | 22 | $1,737 | $79 |
| Erythromycin | 70 | $932 | $13 |
| Prednisolone Acetate | 21 | $671 | $32 |
| Latanoprost | 61 | $585 | $10 |
| Dorzolamide | 28 | $557 | $20 |
| Dorzolamide-Timolol | 24 | $468 | $20 |
| Moxifloxacin | 12 | $290 | $24 |
| Ofloxacin | 14 | $195 | $14 |
| Timolol Maleate | 14 | $113 | $8 |
Year by year
| 2024 | 381 | 154 | 0% (0) | 24% | $48,148 |
| 2023 | 404 | 155 | 0% (0) | None | $65,704 |
| 2022 | 485 | 201 | 0% (0) | 34% | $68,011 |
| 2021 | 421 | 181 | 0% (0) | 32% | $65,179 |
| 2020 | 278 | 113 | 0% (0) | 39% | $48,078 |
| 2019 | 351 | 151 | 0% (0) | 46% | $70,354 |
| 2018 | 410 | 173 | 0% (0) | 53% | $71,192 |
| 2017 | 436 | 173 | 0% (0) | 51% | $60,621 |
| 2016 | 393 | 169 | None | 58% | $68,033 |
| 2015 | 505 | 224 | 0% (0) | None | $66,611 |
| 2014 | 423 | 207 | 0% (0) | 44% | $44,241 |
| 2013 | 429 | 206 | 0% (0) | 44% | $32,447 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Cyclosporine | 14 | $9,476 | $677 |
| Azopt | 14 | $7,351 | $525 |
| Alphagan P | 24 | $5,326 | $222 |
| Travoprost | 15 | $3,021 | $201 |
| Valacyclovir | 33 | $2,314 | $70 |
| Brimonidine | 12 | $2,278 | $190 |
| Latanoprost | 60 | $868 | $14 |
| Erythromycin | 58 | $706 | $12 |
| Tobramycin-Dexamethasone | 13 | $678 | $52 |
| Dorzolamide-Timolol | 20 | $458 | $23 |
| Prednisolone Acetate | 12 | $401 | $33 |
| Dorzolamide | 20 | $394 | $20 |
| Ofloxacin | 20 | $287 | $14 |
2022: 14 drugs
| Restasis | 15 | $16,227 | $1,082 |
| Alphagan P | 27 | $6,532 | $242 |
| Cyclosporine | 11 | $5,961 | $542 |
| Travoprost | 19 | $2,946 | $155 |
| Brimonidine | 16 | $2,138 | $134 |
| Simbrinza | 11 | $2,064 | $188 |
| Tobramycin-Dexamethasone | 21 | $1,427 | $68 |
| Dorzolamide | 38 | $1,071 | $28 |
| Latanoprost | 67 | $1,039 | $16 |
| Erythromycin | 81 | $962 | $12 |
| Valacyclovir | 15 | $750 | $50 |
| Prednisolone Acetate | 16 | $621 | $39 |
| Ofloxacin | 39 | $509 | $13 |
| Dorzolamide-Timolol | 23 | $446 | $19 |
2021: 13 drugs
| Restasis | 30 | $35,535 | $1,184 |
| Combigan | 13 | $3,058 | $235 |
| Brimonidine | 14 | $1,863 | $133 |
| Tobramycin-Dexamethasone | 25 | $1,722 | $69 |
| Erythromycin | 74 | $967 | $13 |
| Latanoprost | 61 | $691 | $11 |
| Dorzolamide | 19 | $666 | $35 |
| Olopatadine | 11 | $577 | $52 |
| Dorzolamide-Timolol | 20 | $571 | $29 |
| Valacyclovir | 11 | $569 | $52 |
| Prednisolone Acetate | 13 | $500 | $38 |
| Ofloxacin | 25 | $329 | $13 |
| Timolol Maleate | 14 | $194 | $14 |
2020: 10 drugs
| Restasis | 13 | $19,451 | $1,496 |
| Pazeo | 22 | $4,582 | $208 |
| Brimonidine | 19 | $2,576 | $136 |
| Simbrinza | 12 | $2,025 | $169 |
| Dorzolamide | 21 | $1,153 | $55 |
| Tobramycin-Dexamethasone | 14 | $1,107 | $79 |
| Latanoprost | 40 | $672 | $17 |
| Erythromycin | 29 | $341 | $12 |
| Ofloxacin | 12 | $147 | $12 |
| Timolol Maleate | 12 | $86 | $7 |
2019: 13 drugs
| Restasis | 23 | $32,469 | $1,412 |
| Xiidra | 16 | $11,091 | $693 |
| Pazeo | 21 | $4,128 | $197 |
| Simbrinza | 22 | $3,748 | $170 |
| Ilevro | 11 | $3,039 | $276 |
| Brimonidine | 34 | $2,819 | $83 |
| Combigan | 14 | $2,796 | $200 |
| Latanoprost | 42 | $1,174 | $28 |
| Tobramycin-Dexamethasone | 15 | $1,060 | $71 |
| Erythromycin | 53 | $584 | $11 |
| Dorzolamide | 15 | $538 | $36 |
| Timolol Maleate | 12 | $327 | $27 |
| Ofloxacin | 16 | $227 | $14 |
2018: 12 drugs
| Restasis | 19 | $23,040 | $1,213 |
| Pazeo | 51 | $9,328 | $183 |
| Ilevro | 18 | $4,639 | $258 |
| Alphagan P | 13 | $3,965 | $305 |
| Brimonidine | 37 | $3,914 | $106 |
| Combigan | 12 | $2,620 | $218 |
| Simbrinza | 11 | $1,644 | $149 |
| Prednisolone Acetate | 18 | $978 | $54 |
| Latanoprost | 35 | $832 | $24 |
| Erythromycin | 63 | $720 | $11 |
| Ofloxacin | 30 | $482 | $16 |
| Dorzolamide | 21 | $467 | $22 |
2017: 11 drugs
| Restasis | 23 | $19,143 | $832 |
| Pazeo | 65 | $10,852 | $167 |
| Bepreve | 11 | $3,972 | $361 |
| Alphagan P | 17 | $2,636 | $155 |
| Brimonidine | 20 | $2,117 | $106 |
| Tobramycin-Dexamethasone | 13 | $1,201 | $92 |
| Latanoprost | 63 | $1,117 | $18 |
| Erythromycin | 57 | $629 | $11 |
| Ofloxacin | 29 | $547 | $19 |
| Dorzolamide-Timolol | 11 | $359 | $33 |
| Timolol Maleate | 16 | $179 | $11 |
2016: 9 drugs
| Restasis | 34 | $31,162 | $917 |
| Pazeo | 64 | $10,006 | $156 |
| Alphagan P | 26 | $5,561 | $214 |
| Pataday | 20 | $4,207 | $210 |
| Lotemax | 11 | $2,527 | $230 |
| Tobramycin-Dexamethasone | 26 | $2,301 | $88 |
| Latanoprost | 52 | $643 | $12 |
| Erythromycin | 37 | $428 | $12 |
| Ofloxacin | 17 | $281 | $17 |
2015: 15 drugs
| Restasis | 33 | $21,320 | $646 |
| Travatan Z | 26 | $7,509 | $289 |
| Lumigan | 14 | $5,305 | $379 |
| Alphagan P | 22 | $4,297 | $195 |
| Pataday | 21 | $3,981 | $190 |
| Tobramycin-Dexamethasone | 46 | $3,968 | $86 |
| Ilevro | 17 | $3,726 | $219 |
| Lotemax | 13 | $2,098 | $161 |
| Vigamox | 11 | $1,499 | $136 |
| Timolol Maleate | 24 | $969 | $40 |
| Latanoprost | 81 | $826 | $10 |
| Prednisolone Acetate | 15 | $688 | $46 |
| Erythromycin | 52 | $630 | $12 |
| Ofloxacin | 26 | $405 | $16 |
| Dorzolamide | 11 | $266 | $24 |
2014: 12 drugs
| Restasis | 23 | $14,037 | $610 |
| Pataday | 21 | $4,395 | $209 |
| Tobramycin-Dexamethasone | 34 | $3,466 | $102 |
| Alphagan P | 18 | $3,085 | $171 |
| Lumigan | 11 | $2,152 | $196 |
| Travatan Z | 11 | $1,835 | $167 |
| Vigamox | 15 | $1,715 | $114 |
| Erythromycin | 88 | $1,238 | $14 |
| Prednisolone Acetate | 18 | $834 | $46 |
| Ketorolac Tromethamine | 34 | $767 | $23 |
| Latanoprost | 22 | $373 | $17 |
| Ofloxacin | 27 | $199 | $7 |
2013: 11 drugs
| Restasis | 13 | $5,894 | $453 |
| Pataday | 35 | $4,369 | $125 |
| Tobramycin-Dexamethasone | 33 | $3,183 | $96 |
| Vigamox | 24 | $2,401 | $100 |
| Travatan Z | 15 | $1,895 | $126 |
| Ketorolac Tromethamine | 60 | $1,385 | $23 |
| Erythromycin | 81 | $1,213 | $15 |
| Latanoprost | 16 | $640 | $40 |
| Brimonidine | 11 | $608 | $55 |
| Prednisolone Acetate | 24 | $452 | $19 |
| Ofloxacin | 38 | $328 | $9 |
Money from drug and device companies
$634 in 2025
| 2025 | 7 | 16 | None | $634 |
| 2024 | 12 | 21 | None | $901 |
| 2023 | 7 | 11 | None | $654 |
| 2022 | 4 | 7 | None | $232 |
| 2021 | 7 | 8 | None | $352 |
| 2020 | 3 | 3 | None | $63 |
| 2019 | 6 | 10 | None | $531 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotissue Holdings | None | $140 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $137 | 4 payments
|
| Alcon Vision | Tryptyr | $123 | 1 payment
|
| Astellas Pharma US | Izervay | $77 | 3 payments
|
| Abbvie | Ozurdex | $75 | 3 payments
|
| Amgen | Tepezza | $54 | 3 payments
|
See all 16 published payments
| Astellas Pharma US | Meals · 2025-11-18 | Izervay | $25 |
| Amgen | Meals · 2025-10-16 | Tepezza | $16 |
| Biotissue Holdings | Meals · 2025-09-24 | None | $140 |
| Alcon Vision | Meals · 2025-07-23 | Tryptyr | $123 |
| Astellas Pharma US | Meals · 2025-07-22 | Izervay | $22 |
| Amgen | Meals · 2025-06-03 | Tepezza | $18 |
| Amgen | Meals · 2025-05-21 | Tepezza | $20 |
| Harrow Eye | Meals · 2025-05-15 | Iheezo | $28 |
| Bausch & Lomb Americas | Meals · 2025-05-07 | Vyzulta | $5 |
| Bausch & Lomb Americas | Meals · 2025-05-07 | Vyzulta | $4 |
| Abbvie | Meals · 2025-04-17 | Ozurdex | $25 |
| Bausch & Lomb Americas | Education · 2025-03-14 | Xiidra | $3 |
| Bausch & Lomb Americas | Meals · 2025-03-12 | Vyzulta | $125 |
| Abbvie | Meals · 2025-03-04 | Lumigan | $25 |
| Abbvie | Meals · 2025-01-23 | Ozurdex | $26 |
| Astellas Pharma US | Meals · 2025-01-08 | Izervay | $30 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $901
| Astellas Pharma US | Izervay | $280 | 6 payments
|
| Bausch & Lomb Americas | Vyzulta | $138 | 3 payments
|
| Genentech | Vabysmo | $116 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $109 | 1 payment
|
| Abbvie | Lumigan | $66 | 2 payments
|
| Alcon Vision | Rocklatan | $47 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $31 | 1 payment
|
| Genentech USA | Vabysmo | $28 | 1 payment
|
| Harrow Eye | Iheezo | $27 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $21 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $19 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $19 | 1 payment
|
2023: $654
| Mallinckrodt Hospital Products | Acthar | $158 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $123 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $123 | 1 payment
|
| Genentech USA | Vabysmo | $122 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $67 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $35 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $28 | 1 payment
|
2022: $232
| Regeneron Healthcare Solutions | Eylea | $136 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $61 | 3 payments
|
| Genentech USA | Vabysmo | $20 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $15 | 1 payment
|
2021: $352
| Regeneron Healthcare Solutions | Eylea | $131 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $122 | 1 payment
|
| Tissuetech | Prokera | $28 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $25 | 1 payment
|
| Genentech USA | Lucentis | $18 | 1 payment
|
| Alcon Vision | Clareon | $16 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $14 | 1 payment
|
2020: $63
| Regeneron Healthcare Solutions | Eylea | $27 | 1 payment
|
| Ocular Therapeutix | Dextenza | $20 | 1 payment
|
| Genentech USA | Lucentis | $16 | 1 payment
|
2019: $531
| Novartis Pharmaceuticals | Beovu | $239 | 4 payments
|
| Mallinckrodt Enterprises | Acthar | $121 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $104 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $25 | 1 payment
|
| Genentech USA | Lucentis | $22 | 1 payment
|
| Shire North American Group | Xiidra | $19 | 1 payment
|
Checkups this office reported
7 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 95.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Checked for fall riskOlder patients screened for fall risk | 70%That's more than half. | 1,474 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 100%That's most of the people this applied to. | 454 |
| Glaucoma Intraocular Pressure ReductionAs Medicare defines this measure | 91% | 35 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 4,057 |
| Overuse of Imaging for the Evaluation of Primary HeadacheAs Medicare defines this measure | 0% | 115 |
| Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of CareAs Medicare defines this measure | 100% | 42 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 1,546 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Create and Implement a Language Access Plan
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1326224528
- Licence
- NY 247235
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0109X (207WX0109X); Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 2500 Pond Vw, Suite 101, S Schodack, NY, 12033
- NPI first listed
- 2008-01-17
- NPI last updated
- 2017-10-16
This is when the NPI record was last certified, not a medical board exam.